MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines.

Abstract excerpt

Renal cell cancers (RCC) are notoriously resistant to chemotherapy and radiotherapy. While mutations of the p53 tumor suppressor gene frequently contribute to therapy resistance in other epithelial cancers, p53 mutations are relatively rare in RCC. To date, there is conflicting evidence as to whether p53 signaling and function are otherwise proficient or defective in tumors with wild-type p53. In this study, we...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma, Renal Cell
• Share to Cell Death
• Share to Cyclin-Dependent Kinase Inhibitor p21